NCT00524849View on ClinicalTrials.gov

Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 30, 2006

Primary Completion Date

August 31, 2008

Study Completion Date

January 31, 2010

Conditions
Metastatic Breast CancerBone Metastases
Interventions
BIOLOGICAL

Zoledronic acid

Zometa 1 mg weekly (intravenous)

DRUG

Zoledronic acid

Zometa 4 mg every four weeks (intravenous)

Trial Locations (1)

200032

Fudan University Cancer Hospital, Shanghai

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Fudan University

OTHER